Neoadjuvant Therapy for Stage IIB Invasive Ductal Carcinoma Breast Cancer

General Approach to Neoadjuvant Therapy

The National Comprehensive Cancer Network recommends neoadjuvant therapy for stage IIB breast cancer as it can downstage tumors, potentially allowing for breast conservation surgery in patients who would otherwise require mastectomy 1, 2
The regimen should be selected based on the tumor's receptor status (ER/PR and HER2) 3, 4
Neoadjuvant therapy provides the opportunity to assess tumor response in vivo, which has prognostic significance 5, 6

For HER2-Negative, Hormone Receptor-Positive Disease, the American College of Surgeons recommends a standard anthracycline-taxane sequence: AC (doxorubicin/cyclophosphamide) for 4 cycles followed by weekly paclitaxel or docetaxel 1, 7
For HER2-Positive Disease, the European Society for Medical Oncology recommends AC followed by paclitaxel plus trastuzumab and pertuzumab (dual HER2 blockade) 3, 4
For Triple-Negative Breast Cancer, the National Comprehensive Cancer Network recommends the KN522 protocol: chemotherapy with taxanes, carboplatin, anthracyclines, cyclophosphamide, combined with concurrent pembrolizumab 9

The American Society of Clinical Oncology recommends percutaneous placement of clips into the breast under imaging guidance before starting neoadjuvant therapy to mark the tumor site for subsequent surgery 2, 10
The National Comprehensive Cancer Network recommends sentinel lymph node biopsy may be performed before or after neoadjuvant therapy, with prechemotherapy biopsy providing additional information to guide treatment decisions 5, 2
Cardiac monitoring is essential when using anthracycline-based regimens or trastuzumab, as recommended by the American Heart Association 1

The European Society for Medical Oncology reports that pathologic complete response rates vary by subtype: approximately 55-65% for HER2-positive disease with dual blockade 8
Higher pCR rates correlate with improved long-term outcomes, particularly for HER2-positive and triple-negative subtypes, as reported by the National Comprehensive Cancer Network 8
Breast conservation surgery rates are significantly higher after effective neoadjuvant therapy, according to the American College of Surgeons 2